.
MergerLinks Header Logo

Announced

Goldman Sachs to invest $150m in Biocon Biologics at a $3.9bn valuation.

Financials

Edit Data
Transaction Value£113m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private Equity

Cross Border

Pending

Acquisition

Private

oncology

Minority

Friendly

India

Pharmaceuticals

cancer research

biopharmaceuticals

Single Bidder

Synopsis

Edit

Goldman Sachs agreed to invest $150m in Biocon Biologics, a biopharmaceutical company, at a $3.9bn valuation. "We are extremely pleased to welcome a capital injection by Goldman Sachs at this inflection point of Biocon Biologics’ journey in its quest for global leadership in providing affordable access through Biosimilar drugs. This transaction is a part of the overall strategic plan of value creation for our shareholders through Biocon Biologics,” Kiran Mazumdar-Shaw, Biocon Executive Chairman.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US